Speaker
Description
We examine MXenes as optical absorption agents for photothermal treatment (PTT) in this study. To ensure targeted delivery of MXenes, we linked them to the monoclonal anti-CEACAM1 antibody (mAb).
Our study uses an NIR-I laser to evaluate the targeted photothermal effect in vitro and to offer biological characterization of the MXene-anti-CEACAM1 antibody combination. After polydopamine (PDA) of varying thicknesses was added to delaminated Ti3C2Tx MXenes, human anti-CEACAM1 mAb was immobilized. The complex's specificity, affinity, biocompatibility, and selective photothermal ablation were all examined.
Our findings show that after 4 and 24 hours of incubation with various melanoma cell types and keratinocytes, the MXene-anti-CEACAM1 complex and its constituent parts (MXenes, MXene-PDA, and anti-CEACAM1 mAb) do not exhibit any cytotoxicity. Our findings show that thickening the PDA layer decreases photothermal conversion but has no effect on biocompatibility, specificity, or affinity. Modes of laser irradiation were chosen experimentally to safely affect non-targeted cells while also successfully influencing the complex. When target cells are loaded with MXene-PDA-anti-CEACAM1 mAb complexes, highly selective tumor cell ablation utilizing near-infrared irradiation (NIR) is seen.
We concluded that the use of a combination of MXene-anti-CEACAM1 mAb for selective PTT of tumor cells has significant potential for creating a new model of targeted treatment of melanoma.
Acknowledgements. This research is supported from the HORIZON-MSCA-2021-SE-01 (Project #101086184) and MSCA4Ukraine project (Project #1232462).
Keywords: MXenes, cancer treatment, targeted photothermal ablation
